EQUILLIUM, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
EQUILLIUM, INC. (EQ) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$4.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-25
- EQUILLIUM, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$4.70M.
- EQUILLIUM, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$1.62M.
- EQUILLIUM, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$2.68M.
- EQUILLIUM, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$13.11M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$4.70M 10-K · filed 2026-03-25 |
| 2024-12-31 | -$1.62M 10-K · filed 2026-03-25 |
| 2023-12-31 | -$2.68M 10-K · filed 2025-03-27 |
| 2022-12-31 | -$13.11M 10-K · filed 2024-03-25 |
| 2021-12-31 | -$8.20M 10-K · filed 2023-03-23 |
| 2020-12-31 | -$6.26M 10-K · filed 2022-03-23 |
| 2019-12-31 | -$5.38M 10-K · filed 2021-03-24 |
| 2018-12-31 | -$2.78M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |